Positive outlook for CDMOs at CPhI North America, but companies need to be ready for challenges

CPhI North America, running concurrently with InformEx, is a new addition to the global series of CPhI events.

Read more >

DCAT Week ’17 session looks at emerging pharma market trends

The health of emerging pharmaceutical companies can be assessed, in part, by financing and partnership activity with larger companies, Richard Harrison, Chief Scientific Officer at Clarivate Analytics, told a DCAT Week ’17 audience in a session titled “Emerging Pharma: Market Overview, Project Management and CMC Readiness.”

Read more >

Latin American market presents attractive opportunities in innovation and generics, but adaptability is key

The combined populations of the three most populous countries in Latin America – Brazil, Mexico, and Colombia – account for more than 350 million people. Pharmaceutical companies have long sought access to the growing market in Latin America and many have faced difficulties in doing so.

Read more >

DCAT Week '16: Transformational Sourcing

With a mandate from Amgen’s senior team to develop the best supply chain system in the world, Rodney MacLea (Amgen) began by explaining that his teams approach was very much based around learning from industries with larger, more complex but mature supply chains. For example, Amgen’s most complex products involve a few hundred components whereas the aerospace industry routinely builds aircraft with nearly 40,000 individual items. Amgen requires total supply chain knowledge, from end-to-end; tracking partnerships, source visibility, risk and risk mitigation; performance (of materials) and leverages advanced monitoring technologies to achieve this view. Much of this knowledge has been gained through supplier mapping, where a suppliers sources are mapped, and potentially the supplier’s supplier in cases where products or components are particularly critical.

Read more >

DCAT Week '16: Pharmaceutical Outsourcing - The Markets and Supply Strategies for Fine Chemicals, APIs, and Drug Products

The balance between internal manufacturing and development and external sourcing for APIs, fine chemicals, and drug products is a difficult task to manage. This is further complicated by the increasing M&A activity and complexities within the supply chain forcing each company to strongly evaluate their partners and what they choose to produce in house or source through 3rd party vendors.

Read more >